About the Citizen Briefs
The citizen brief is central to reclaiming the role of the citizen in the body politics. It is a stand alone document addressing a particular societal challenge, i.e the opioid epidemic. The citizen brief is utilized to establish a framework for a citizen oriented treatment plan that provides a comprehensive, multi stakeholder and multi phase road map for citizen involvement in their political ecosystem. It is best used as part of The Medical Case Presentation. The complete citizen brief provides a vision for the issue reframes a problem, provides data, discusses the various issues and proposes actions that can be undertaken by the citizen to address the problem.
At our current political moment, the biology and politics of Cannabis provide a unique window and opportunity to explore and learn about politics of the US political system in general using cannabis as a case study. The corruption of the political ecosystem is highlighted and the case helps to appreciate the role of government, the federalism based system and the potential for citizen engagement within the body politic.
The Medical Cannabis Case and Treatment Plan are a framework for a citizen oriented approach to the challenges facing us in the Body Politics of the United States. Using the Citizen Brief and the Medical Case Presentation as an organizing structure, the Cannabis Case offers a dynamic, interactive, collaborative process that engages our fellow citizens to address the Cannabis related challenges confronting us as individuals, members of our community and citizens of the nation. It provides a vehicle for citizens to collaborate, identify, analyze, develop, implement and monitor a solution-based “treatment plan” for medical problems. In addition, the Cannabis Case serves to test the proposition that with the proper framework and easy to use citizen oriented tools, we can more effectively collaborate to address complex problems. While the Cannabis Case effort is measured in terms of predetermined outcomes associated with the legalization of Medical Cannabis and the social and political challenge of the consequences of the political process, a major focus of this process is to examine the framework of the Case Presentation as a tool to enhance citizen participation and engagement in the “political ecosystem”.
Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain and other medical conditions. There is a theoretical rationale for cannabis’ efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence to evaluate this increase. Our goal is to be a comprehensive destination for Medical Cannabis information and tools as well as provide a framework for citizen engagement in the Cannabis Ecosystem.
By September 2020, every individual who experiences medical conditions and symptoms that prevent them from optimal health has access to and is able to receive evidence based, best practice informed treatment that improves their wellbeing in outcomes that matter for them.
Individuals and communities that were victims of the war on drugs will have their legal status restored and efforts to address the consequences of the actions by police and federal agencies.
Citizens4health Cannabis Project is driven by a vision of individuals who live in a state of optimal wellbeing and health and flourish as individuals living in their community and are engaged in their political ecosystem.
Marijuana has languish as a Schedule I drug with a “high potential for abuse, no accepted medical use, and no accepted safety for use in medically supervised treatment,”104 the federal government thumbs an illogical nose at contemporary public sentiment, recent scientific discoveries, and potentially head-to-toe therapeutic breakthroughs.
This reclassification would be a first step toward reconciling federal and state law and permitting long-stifled research into a potential trove of therapeutic applications to commence.
The absence of a sensible, stable federal marijuana policy affects the safety of marijuana products and physicians’ comfort in recommending or prescribing them. Although the FDA has an approval track for botanicals, only one purified plant-based marijuana product is currently regulated by the FDA.1 Inconsistency in marijuana regulation from state to state can allow inappropriate marketing, formulation, and packaging practices to persist — making THC content across samples unpredictable, for instance, or permitting marketing of edibles that appeal to children.4 Without FDA approval, a lack of information about efficacy, dosing, adverse effects, and availability of marijuana products deters providers from recommending them.
The present state of conflicting laws seems unstable and suboptimal for rational drug control. Federal regulation that accommodates and reinforces state medical marijuana regulatory regimes would result in a safer, more reliable, more accessible supply of marijuana products.